- Home
- ABOS vs UNCY Comparison
ABOS vs UNCY Comparison
Compare ABOS & UNCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ABOS | UNCY |
|---|---|---|
| Founded | 1996 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 155.7M | 145.3M |
| IPO Year | 2021 | 2021 |
Fundamental Metrics
Financial Performance| Metric | ABOS | UNCY |
|---|---|---|
| Price | $2.59 | $6.37 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 4 |
| Target Price | $7.75 | ★ $44.50 |
| AVG Volume (30 Days) | ★ 473.4K | 432.4K |
| Earning Date | 05-12-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 56.25 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $675,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.86 | $0.45 |
| 52 Week High | $3.60 | $7.57 |
Technical Indicators
Market Signals| Indicator | ABOS | UNCY |
|---|---|---|
| Relative Strength Index (RSI) | 38.37 | 42.00 |
| Support Level | $1.21 | $5.90 |
| Resistance Level | $3.05 | $6.82 |
| Average True Range (ATR) | 0.26 | 0.30 |
| MACD | -0.11 | -0.06 |
| Stochastic Oscillator | 5.56 | 4.22 |
Price Performance
Historical ComparisonAbout ABOS Acumen Pharmaceuticals Inc.
Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers.
About UNCY Unicycive Therapeutics Inc.
Unicycive Therapeutics Inc is a biotechnology company dedicated to developing treatments for certain medical conditions. It is focusing on kidney diseases. The company's manufactures drug, Renazorb, is a novel phosphate-binding agent being developed for the treatment of hyperphosphatemia. Unicycive's other drug, UNI-494, is a new chemical entity with the issued composition of matter patent protection in late preclinical development for the treatment of acute kidney injury. Company's pipeline comprised of two product candidates: Oxylanthanum Carbonate and UNI-494.